FilingReader Intelligence
Livzon reports growth, new investments, expands share buyback program
April 23, 2025 at 05:02 PM UTC•By FilingReader AI
** Livzon Pharmaceutical Group Inc. (HKEX: 1513) reported its 2024 financial results, showcasing a net profit attributable to shareholders of the company of RMB2.0611 billion, a 5.5% year-on-year increase. To reward shareholders and demonstrate confidence in the company's prospects, the Board recommends a cash dividend of RMB11.00 per 10 shares.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
(I) CAPITAL CONTRIBUTION TO LIVZONBIO (II) 2024 ANNUAL PROFIT DISTRIBUTION PLAN (III) PROPOSED FACILITY FINANCING AND PROVISION OF FINANCING GUARANTEES TO SUBSIDIARIES (IV) PROPOSED RENEWAL OF THE REPURCHASE OF PART OF THE COMPANY'S A SHARES SCHEME (V) PROPOSED GRANT OF GENERAL MANDATE TO THE BOARD TO REPURCHASE H SHARES (VI) CONVENING THE AGM, THE CLASS MEETING OF A SHAREHOLDERS AND THE CLASS MEETING OF H SHAREHOLDERSApril 23, 2025 at 10:06 AM UTC
2024 Environmental, Social and Governance ReportApril 23, 2025 at 10:06 AM UTC
CANCELLATION OF SHARE OPTIONS UNDER THE 2022 SHARE OPTIONS INCENTIVE SCHEMEApril 23, 2025 at 10:20 AM UTC
APPOINTMENT OF SENIOR EXECUTIVEApril 23, 2025 at 10:35 AM UTC
RESIGNATION OF SENIOR EXECUTIVE OF THE COMPANYApril 23, 2025 at 10:35 AM UTC
Final Dividend for the year ended 31 December 2024 (Update)April 23, 2025 at 10:35 AM UTC
2025 FIRST QUARTERLY REPORTApril 23, 2025 at 10:49 AM UTC
HKEX:1513•Hong Kong Exchange
News Alerts
Get instant email alerts when Livzon Pharmaceutical Group Inc publishes news
Free account required • Unsubscribe anytime